Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma

References

• Ozols RF. Optimum chemotherapy for ovarian cancer. International Journal of Gynecological Cancer 2000; 10: 33–37
   PubMed Web of Science ®Google Scholar
• McGuire WP, Brady MF, Ozols RF. The Gynecologic Oncology Group experience in overian cancer. Annals of Oncology 1999; 10(Suppl 1)29–34
   PubMedGoogle Scholar
• Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Annals of Oncology 2001; 12: 1195–1203
   PubMed Web of Science ®Google Scholar
• Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. Journal of Clinical Oncology 1987; 5: 756–767
   PubMed Web of Science ®Google Scholar
• MacGibbon A, Bucci J, MacLeod C, Solomon J, Dalrymple C, Firth I, Carter J. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. Gynecology & Oncology 1999; 75: 62–67
   PubMedGoogle Scholar
• Firat S, Murray K, Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. International Journal of Radiation Oncology, Biology & Physics 2003; 57: 201–207
   PubMedGoogle Scholar
• Sedlacek TV, Spyropoulus P, Cifaldi R, Glassburn J, Fisher S. Whole-abdomen radiation therapy as salvage treatment for epithelial ovarian carcinoma. Cancer Journal of Science America 1997; 3: 358–363
   PubMedGoogle Scholar
• Runowicz CD. To P32 or not to P32, that is the question. Gynecology & Oncology 1993; 50: 139–140
   PubMedGoogle Scholar
• Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine 1996; 335: 1950–1955
   PubMed Web of Science ®Google Scholar
• Recio FO, Piver MS, Hempling RE, Driscoll DL. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecology & Oncology 1998; 68: 267–273
   PubMedGoogle Scholar
• Dedrick RL, Myers CE, Bungay PM, DeVita VT, Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports 1978; 62: 1–11
   PubMedGoogle Scholar
• Piver MS, Lele SB, Marchetti DL, Baker TR, Emrich LJ, Hartman AB. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. Journal of Clinical Oncology 1988; 6: 1679–1684
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Santin AD, O’Brien TJ. Immunological treatment of ovarian cancer. Current Opinions in Obstetrics & Gynecology 2004; 16: 87–92
   PubMed Web of Science ®Google Scholar
• Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. Journal of Clinical Oncology 2003; 21(10 Suppl)168–174
   PubMedGoogle Scholar
• Leopold KA, Oleson JR, Clarke-Pearson D, Soper J, Berchuck A, Samulski TV, Page RL, Blivin J, Tomberlin JK, Dewhirst MW. Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. International Journal of Radiation Oncology, Biology & Physics 1993; 27: 1245–1251
   PubMed Web of Science ®Google Scholar
• Westermann AM, Grosen EA, Katschinski DM, Jager D, Rietbroek R, Schink JC, Tiggelaar CL, Jager E, Zum Vorde sive Vording P, Neuman A, Knuth A, Van Dijk JD, Wiedemann GJ, Robins HI. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. European Journal of Cancer 2001; 37: 1111–1117
   PubMed Web of Science ®Google Scholar
• Van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, Ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. European Journal of Cancer 1998; 34: 148–154
   PubMed Web of Science ®Google Scholar
• Formenti SC, Shrivastava PN, Sapozink M, Jozsef G, Chan KK, Jeffers S, Morrow PC, Muggia FM. Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: Feasibility, tolerance and pharmacology. International Journal of Radiation Oncology, Biology & Physics 1996; 35: 993–1001
   PubMedGoogle Scholar
• Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis JL, Barakat R, Rubin S, Mychalczak B, Saigo P, Almadrones L, Hoskins W. Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 1993; 71(4 Suppl)1565–1570
   PubMedGoogle Scholar
• Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001; 19: 1001–1007
   PubMed Web of Science ®Google Scholar
• Spratt JS, Adcock RA, Sherrill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Research 1980; 40: 253–255
   PubMed Web of Science ®Google Scholar
• Smith GV, MacMillan R, Stribling J. Intraperitoneal approach to regional hyperthermia—possible anticancer applications. World Journal of Surgery 1983; 7: 732–737
   PubMed Web of Science ®Google Scholar
• Herman TS. Temperature dependence of adriamycin, cis-diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Research 1983; 43: 517–520
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, Loo TL. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemotherapy & Pharmacology 1982; 10: 51–54
   PubMed Web of Science ®Google Scholar
• Herman TS, Teicher BA, Chan V, Collins LS, Abrams MJ. Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes. International Journal of Radiation Oncology, Biology & Physics 1989; 16: 443–449
   PubMed Web of Science ®Google Scholar
• Wallner KE, Li GC. Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Research 1987; 47: 493–495
   PubMed Web of Science ®Google Scholar
• Eichholtz-Wirth H, Hietel B. Heat sensitization to cisplatin in two cell lines with different drug sensitivities. International Journal of Hyperthermia 1990; 6: 47–55
   PubMed Web of Science ®Google Scholar
• Mansouri A, Henle KJ, Benson AM, Moss AJ, Nagle WA. Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia. Cancer Research 1989; 49: 2674–2678
   PubMed Web of Science ®Google Scholar
• Howell SB, Kirmani S, McClay EF, Kim S, Braly P, Plaxe S. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. Seminars in Oncology 1991; 18(1 Suppl 3)5–10
   PubMedGoogle Scholar
• Hebert ME, Blivin JL, Kessler J, Soper JT, Oleson JR. Anaphylactoid reactions with intraperitoneal cisplatin. Annals of Pharmacotherapy 1995; 29: 260–263
   PubMedGoogle Scholar
• Piver M, Fanning J, Craig K. Ovarian cancer. Gynecologic oncology, 2nd ed., R Berkowitz, R Knapp. McGraw-Hill, New York 1993; 250–292
   Google Scholar
• Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB. Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come: a theraphy whose time has come!. Journal of Clinical Oncology 2002; 20: 3944–3946
   PubMedGoogle Scholar
• Vergote I, Piccart M, Scafone G, et al. Randomized phase III EORTC-GCG study comparing intraperitoneal (ip) cisplatin (p) versus observation in ovarian cancer (O.C.) patients (pts) with a pathologically complete remission (pCR) after first-line chemotherapy. Proceedings from the 2004 Annual Meeting of the Society of Gynecologic Oncologists
   Google Scholar
• Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 2006; 100: 27–32
   PubMed Web of Science ®Google Scholar